Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
Public ClinicalTrials.gov record NCT00637130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and IOP Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions Dosed BID Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.
Study identification
- NCT ID
- NCT00637130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- Travoprost ophthalmic solution, 0.0008% Drug
- Travoprost ophthalmic solution, 0.001% Drug
- Travoprost ophthalmic solution, 0.0012% Drug
- TRAVATAN Drug
- Vehicle Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2007
- Primary completion
- Dec 31, 2007
- Completion
- Not listed
- Last update posted
- Dec 5, 2012
Started 2007
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Contact Alcon Call Center at 1-888-451-3937 | Fort Worth | Texas | 76134 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Open-angle Glaucoma trials
Other public records listing Open-angle Glaucoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT05506423: Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes Active, not recruiting
- NCT07619482: Topical Insulin for Glaucoma (TING2) Not yet recruiting
- NCT07325240: 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Recruiting
- NCT04499248: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Recruiting
- NCT07217678: Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use Recruiting
- NCT07228221: Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00637130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2012 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00637130 live on ClinicalTrials.gov.